Vor Biopharma VOR 深 沪
等待开盘 08-13 09:30:00 美东时间
1.66
-0.330
-16.58%
华盛通- 最 高1.96
- 今 开1.96
- 成交量 664.17万股
- 最 低 1.62
- 昨 收 1.99
- 总市值 2.08亿
- 52周最高 3.29
- 市盈率 静 --
- 换手率 5.31%
- 52周最低 0.1311
- 委 比 79.98%
- 总股本 1.25亿
- 历史最高 63.62
- 量 比 2.67
- 振 幅 17.09%
- 历史最低 0.1311
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vor Biopharma Q2 Adj. EPS $(2.19) Misses $(0.22) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(0.22) by 877.68 percent. This is a 434.15 percent decrease over losses of $(0.41) per share from
今天 05:54
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Vor Bio has appointed Dallan Murray as Chief Commercial Officer to lead the global market readiness and launch strategy for telitacicept, a novel treatment for autoimmune diseases. Murray, with over 25 years of experience in biotech and pharma, joins from Sarepta Therapeutics, where he oversaw significant product launches, including the first RNA and gene therapies. He will focus on preparing for telitacicept's global commercialization, currently...
08-04 12:30
Vor Biopharma Announces Key Leadership Changes
An update from Vor Biopharma ( ($VOR) ) is now available. On July 17, 2025, Vor...
07-23 05:31
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns.
07-21 19:45
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Vor Bio announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors. Bo Cumbo, CEO of Solid Biosciences, brings over 30 years of commercial and executive leadership in biotech. Michel Detheux, CEO of iTeos Therapeutics, has extensive experience in drug development and partnerships, including a $2 billion deal with GSK. Their expertise will support Vor Bio's advancement of telitacicept for autoimmune dise...
07-21 12:30
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.
07-18 00:10
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Vor Bio announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer. Dr. Zuraw brings over 25 years of experience in leading global clinical development programs for autoimmune diseases, including the successful development and regulatory approvals of telitacicept in China for systemic lupus erythematosus (SLE), myasthenia gravis (MG), rheumatoid arthritis (RA), and Sjögren’s syndrome at RemeGen. Her expertise will...
07-17 12:30
Powerfleet Launches Automated AI Risk Intervention Module for Driver Safety
WOODCLIFF LAKE, N.J., July 10, 2025 /PRNewswire/ -- Powerfleet, Inc. (Nasdaq: AIOT), a global leader in the artificial intelligence of things (AIoT) software-as-a-service (SaaS) mobile asset...
07-11 04:15
Vor Bio appoints Sandy Mahatme as CFO
Vor Bio (NASDAQ:VOR) announced on Thursday the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mahatme joins Vor Bio with more than 30 years...
07-11 04:07
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
Vor Bio appoints Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. With over 30 years of experience in the biopharmaceutical industry, Mahatme brings expertise in capital markets, business development, and operational leadership. He joins Vor Bio as it advances telitacicept through global Phase 3 development for autoimmune diseases. Mahatme previously served as President, COO, and CFO of National Resilie...
07-10 20:00
